Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy

BACKGROUND—: Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na(+) current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro. ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circ Heart Fail
Autors principals: Coppini, Raffaele, Mazzoni, Luca, Ferrantini, Cecilia, Gentile, Francesca, Pioner, Josè Manuel, Laurino, Annunziatina, Santini, Lorenzo, Bargelli, Valentina, Rotellini, Matteo, Bartolucci, Gianluca, Crocini, Claudia, Sacconi, Leonardo, Tesi, Chiara, Belardinelli, Luiz, Tardiff, Jil, Mugelli, Alessandro, Olivotto, Iacopo, Cerbai, Elisabetta, Poggesi, Corrado
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6284403/
https://ncbi.nlm.nih.gov/pubmed/28255011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCHEARTFAILURE.116.003565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars